SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q A-1
(Mark One)
X Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934. For the quarterly period ended September 30, 1994.
Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934. For the transition period from to .
Commission File Number
1-9813
GENENTECH, INC.
(Exact name of registrant as specified in its charter)
Delaware 94-2347624
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification number)
460 Point San Bruno Boulevard, South San Francisco, California 94080
(Address of principal executive offices and zip code)
(415) 225-1000
(Registrant's telephone number, including area code)
<PAGE>
GENENTECH, INC.
PART II. OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
27 Financial Data Schedule
<PAGE>
GENENTECH, INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: December 29, 1994 GENENTECH, INC.
/S/G. KIRK RAAB /S/LOUIS J. LAVIGNE, JR.
------------------------------------- --------------------------
G. Kirk Raab Louis J. Lavigne, Jr.
President and Chief Executive Officer Senior Vice President and
Chief Financial Officer
/S/BRADFORD S. GOODWIN
-----------------------------
Bradford S. Goodwin
Vice President and Controller
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
consolidated balance sheets, consolidated statements of income and consolidated
statements of cash flows included in the Company's Form 10-Q for the nine month
period ended September 30, 1994, and is qualified in its entirety by reference
to such financial statements and the notes thereto.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1994
<PERIOD-START> JAN-01-1994
<PERIOD-END> SEP-30-1994
<CASH> 38,307
<SECURITIES> 836,451
<RECEIVABLES> 131,069
<ALLOWANCES> 5,046
<INVENTORY> 100,810
<CURRENT-ASSETS> 891,008
<PP&E> 682,887
<DEPRECIATION> 202,785
<TOTAL-ASSETS> 1,634,590
<CURRENT-LIABILITIES> 190,086
<BONDS> 150,584
<COMMON> 2,332
0
0
<OTHER-SE> 1,280,913
<TOTAL-LIABILITY-AND-EQUITY> 1,634,590
<SALES> 442,927
<TOTAL-REVENUES> 587,630
<CGS> 71,156
<TOTAL-COSTS> 71,156
<OTHER-EXPENSES> 220,592
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 5,375
<INCOME-PRETAX> 110,238
<INCOME-TAX> 4,410
<INCOME-CONTINUING> 105,828
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 105,828
<EPS-PRIMARY> .89
<EPS-DILUTED> .89
</TABLE>
